Condition: ER+ Breast Cancer · Sponsor: Yale University
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
This description comes directly from the study's public registry record.
Laura Kane · 773-369-6904 · laura.kane@yale.edu
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Lombardi Comprehensive Cancer Center at Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore, Maryland, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx, New York, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06923527